GlassScriptPhysician profile
Whitney Harner
NPI 1255620993
$507.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102.35 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.03 | 2021-2022 | |
| Lilly USA, LLC | $72.21 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.96 | 2021-2022 | |
| Abbott Laboratories | $40.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.98 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $27.83 | 2021-2022 | |
| Novo Nordisk INC | $26.19 | 2021 | |
| Ucb, INC. | $24.21 | 2021-2022 | |
| Biogen, INC. | $15.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.28 | 2021 | |
| Daiichi Sankyo INC. | $14.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Harner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.